Working… Menu

AMG 714 Expanded Access Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03439475
Expanded Access Status : Available
First Posted : February 20, 2018
Last Update Posted : November 15, 2019
Information provided by (Responsible Party):

Tracking Information
First Submitted Date February 14, 2018
First Posted Date February 20, 2018
Last Update Posted Date November 15, 2019
Descriptive Information
Brief Title AMG 714 Expanded Access Program
Official Title Not Provided
Brief Summary Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Celiac Disease
Intervention Biological: AMG 714
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Eligibility Criteria

Inclusion Criteria:


Exclusion Criteria:


Sex/Gender Not Provided
Ages 18 Years and older   (Adult, Older Adult)
Contact: Amgen Call Center 866-572-6436
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03439475
Other Study ID Numbers AMG714 Expanded Access Program
Responsible Party Amgen
Study Sponsor Amgen
Collaborators Not Provided
Investigators Not Provided
PRS Account Amgen
Verification Date November 2019